Pasireotide‐induced hyperglycemia in a patient with Cushing's disease: Potential use of sodium‐glucose cotransporter 2 inhibitor and glucagon‐like peptide‐1 receptor agonist for treatment

Autor:	Kazutoshi Mawatari, Nobuhiko Wada, Masatoshi Nomura, Masato Shikata, Kenji Ashida, Kiyohiko Sakata, Kento Hara, Mamiko Yano, Yuka Goto, Munehisa Tsuruta, Ayako Nagayama, Nao Hasuzawa, Shimpei Iwata
Jazyk:	angličtina
Rok vydání:	2020
Předmět:	medicine.medical_specialty Medicine (General) endocrine system endocrine system diseases Stimulation Case Report sodium‐glucose cotransporter 2 inhibitor Case Reports 030204 cardiovascular system & hematology 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine R5-920 Internal medicine Diabetes mellitus glucagon‐like peptide‐1 receptor agonist medicine Glucagon-like peptide 1 receptor pasireotide Somatostatin receptor business.industry nutritional and metabolic diseases General Medicine Cushing's disease medicine.disease Pasireotide Endocrinology Hypercortisolemia chemistry 030220 oncology & carcinogenesis diabetes mellitus Medicine SGLT2 Inhibitor business hormones hormone substitutes and hormone antagonists
Zdroj:	Clinical Case Reports Clinical Case Reports, Vol 8, Iss 12, Pp 2613-2618 (2020)
ISSN:	2050-0904
Popis:	Pasireotide improves hypercortisolemia and induces hyperglycemia via somatostatin receptor type‐5 stimulation. GLP‐1RA and SGLT2 inhibitor potentially help regulate hyperglycemia in patients with Cushing's disease, especially after pasireotide administration.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::be7f5dde0b524cc6934dbceb436b4e3d http://europepmc.org/articles/PMC7752440 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.